Lundbeck adjusts research strategy to avoid costly phase III mistakes
Lundbeck has woked intensively with biomarkers and more segmentation in the company's clinical studies. The goal is to identify more mistakes in the early phases, to avoid costly slip-ups during phase III trials.
Lundbeck received a thorough dressing down on 25. October 2018, when it revealed that its treatment for drug-resistant schizophrenia had failed in phase III - one hour before the stock exchange closed.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Good biology will lead at Lundbeck
For abonnenter
